-
31.发明申请BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF 审中-公开双酸衍生物作为FXR / TGR5激动剂及其使用方法公开(公告)号：US20160185815A1
公开(公告)日：2016-06-30
申请号：US14951989
申请日：2015-11-25
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
CPC classification number: C07J41/0066 , C07J9/005 , C07J41/0055 , C07J41/0088 , C07J41/0094 , C07J43/003 , C07J43/006 , C07J51/00
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
Abstract translation: 本发明提供式I化合物，包含这些化合物的药物组合物和使用这些化合物预防或治疗FXR介导的或TGR5介导的疾病或病症的方法。
-
32.发明授权公开(公告)号：US09221878B2
公开(公告)日：2015-12-29
申请号：US14469403
申请日：2014-08-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Guoqiang Wang , Jiang Long , In Jong Kim
CPC classification number: A61K38/13 , A61K38/00 , A61K38/21 , A61K45/06 , C07K7/645 , Y02A50/463 , A61K2300/00
Abstract: The present invention relates to novel cyclosporine analogs having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analog compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
Abstract translation: 本发明涉及具有抗HCV的抗病毒活性的新型环孢菌素类似物，可用于治疗HCV感染。 更具体地说，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。
-
公开(公告)号：US20130165641A1
公开(公告)日：2013-06-27
申请号：US13684927
申请日：2012-11-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： In Jong Kim , Tongzhu Liu , Jiang Long , Guoqiang Wang , Yao-Ling Qiu , Heejin Kim , Yanchun Wang , Ly Tam Phan , Yat Sun Or
IPC: C07H17/08
CPC classification number: C07D493/08 , C07F9/65586 , C07H17/08
Abstract: The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
-
公开(公告)号：US20230416268A1
公开(公告)日：2023-12-28
申请号：US18139506
申请日：2023-04-26
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Joseph D. Panarese , Guoqiang Wang , Jing He , Jiang Long , Jun Ma , Bin Wang , Sourav Ghorai
IPC: C07D495/04
CPC classification number: C07D495/04
Abstract: The present invention provides compounds of Formula (I),
pharmaceutical compositions comprising these compounds and methods of using these compounds for treating a metabolic disease or liver condition. The present invention relates generally to compounds and pharmaceutical compositions useful as 17β-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17β-HSD13 and methods for their preparation and use.-
公开(公告)号：US11420976B2
公开(公告)日：2022-08-23
申请号：US17155159
申请日：2021-01-22
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yong He , Xuechao Xing , Guoqiang Wang , Ruichao Shen , Brett Granger , Jiang Long , Yat Sun Or
IPC: C07D491/048 , A61K45/06
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
Patent Agency Ranking
公开(公告)号：US20210261600A1
公开(公告)日：2021-08-26
申请号：US17186447
申请日：2021-02-26
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10968249B2
公开(公告)日：2021-04-06
申请号：US16878329
申请日：2020-05-19
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10450301B2
公开(公告)日：2019-10-22
申请号：US15988806
申请日：2018-05-24
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jing He , Yong He , Xuechao Xing , Jun Ma , Jiang Long , Bin Wang , Yat Sun Or
IPC: A61K31/4375 , A61K31/4725 , C07D401/14 , C07D471/04 , C07D471/08 , C07D417/14 , C07D451/02 , C07D451/06
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US20180362501A1
公开(公告)日：2018-12-20
申请号：US15988763
申请日：2018-05-24
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Brett Granger , Ruichao Shen , Yong He , Xuechao Xing , Jun Ma , Jiang Long , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D491/107 , C07D498/08 , C07D401/04
CPC classification number: C07D401/14 , C07D401/04 , C07D491/107 , C07D498/08
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US10138228B2
公开(公告)日：2018-11-27
申请号：US15597423
申请日：2017-05-17
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Yong He , Ruichao Shen , Xuechao Xing , Brett Granger , Bin Wang , Jun Ma , Jing He , Jiang Long , Guoqiang Wang
IPC: A61K31/42 , C07D413/12
Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
-
-
-
-
-
-
-
-
Search Results
85
records
(took 0.028 seconds)
